

**Supplementary Table 9.** Characteristics of included studies comparing mucoprotective with placebo in key question #8

Studies	Patients	Experiment	Control	Duration	Outcome
Kairaluoma et al. <sup>69</sup> (1987)	Chronic gastritis	Sucralfate (n=79)	Placebo (n=72)	4 weeks	Symptom improvement
Skoubo-Kristensen et al. <sup>70</sup> (1989)	Endoscopic gastritis	Sucralfate (n=35)	Placebo (n=35)	6 weeks	Endoscopic erosion
Haruma et al. <sup>71</sup> (2002)	<i>H. pylori</i> chronic gastritis	Rebamipide (n=53)	Placebo (n=33)	12 months	Histology, gastrin
Han et al. <sup>73</sup> (2015)	Chronic gastritis	Rebamipide (n=89)	Placebo (n=88)	26 weeks	Endoscopic erosion, histology
Kamada et al. <sup>72</sup> (2015)	<i>H. pylori</i> chronic gastritis	Rebamipide (n=82)	Placebo (n=87)	12 months	Histology, gastrin